Trial Profile
A Phase I/II Study of Bortezomib + CHOP in Patients With Advanced Stage Aggressive T Cell or NK/T Cell Lymphomas.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 20 Oct 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 20 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Oct 2006 New trial record.